Objectives: This study aimed to compare the medical effects of raloxifene and GnRH on uterine lyomioma size.
Design: 53 women with uterine lyomioma were participated in this study.
Setting and conduct: This was a randomized controlled trial that it was conducted in Besat hospital in Sanandaj-Iran. Participants were randomly divided into two groups of Raloxifene and GnRH using simple randomization (using computer). 27 patients were allocated inraloxifene group and 26 patients were allocated in GnRH group. Participants and inclusion and exclusion criteria: 61 patients were evaluated in the first step. Then 53 patient were entered to the study. Inclusion criteria included not being menopausal, and having lyomiomas with a minimum size of 40 mm and a maximum of 60 mm in one of the diameters of tumor. Exclusion criteria included having metabolic disease, neoplasia disease, infectious diseases, blood disorders, history of venous thrombosis, liver disease, active rheumatoid arthritis, BMI greater than 30 or less than 18 kg/m2, hormone therapy in the last 6 months, surgery in the last 6 months, hypoechoic or calcified lyomiomas, endometrial abnormalities in sonography, and lesions of the cervix.
Interventions: GnRH group received one dose of GnRH per month (3.75mg intramuscular injection) and raloxifene group received a daily dose of raloxifene 60 mg/orally for 3 months.
Main outcome variables: The size of lyomioma, prior and during the intervention, was determined by a sonographist.